Observational Registry Study of Quality of Life When Treating BTcP With Abstral

Overview

This Observational Registry study is designed to collect self-reported Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program-enrolled patient experience with breakthrough cancer pain (BTcP) as a result of treatment with Abstral® through the use of Quality of Life and pain measurement tools administered via questionnaire.

This is a post-marketing, single arm, open label multicenter trial to assess Abstral (fentanyl) Sublingual Tablets for breakthrough cancer pain (BTcP) in opioid-tolerant cancer patients. * Prior to study enrollment, patient enrollment in the TIRF REMS Access program must be confirmed. * Eligible patients will sign written informed consent. Patients or their proxy with a witness must be able to sign written informed consent to participate in the study; and the patient may use a proxy caregiver to assist in the completion of the study questionnaires. * Day 0, study site must enroll patient by completing a patient demographic profile (de-identified). * Day 0, patient will be instructed how to use the questionnaires. * Day 0, patient will complete the baseline questionnaire before leaving the physician office. * On study Days 14, 21, and 28 (±3 days) patient questionnaire will be completed by patient (or caregiver proxy) via secure online data entry portal. * For patients completing paper questionnaires, within 1 month of day 28, patient will return completed questionnaires via mail, fax or hand carried to the study site coordinator for processing. * Patient will be considered to have completed the study successfully once all completed questionnaires have been received by the CRO within appropriate time limits.

Conditions

Interventions

Eligibility

Locations (36)

Outcomes